Kyowa Kirin said on June 26 that it has received Japanese regulatory approval for a new pen-type formulation of its anti-interleukin-17 (IL-17) receptor A antibody Lumicef (brodalumab).The newly approved Lumicef Subcutaneous Injection 210 mg Pen is a prefilled autoinjector containing…
To read the full story
Related Article
- Kyowa Kirin Files Pen Version of Lumicef in Japan
July 1, 2024
BUSINESS
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
- Retevmo Now Available in Tablet Form: Lilly Japan
December 8, 2025
- Japan Ethical Drug Sales Rise 5.9% in October: Crecon
December 8, 2025
- Takeda Closes Innovent Oncology Deal, Bags Rights to 2 Late-Stage Assets
December 8, 2025
- Santen to Market Bayer’s Eylea Bio-AG; Launch Date Still Undisclosed
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





